Trials / Unknown
UnknownNCT02150317
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma
A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Eastern Hepatobiliary Surgery Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) followed by Sorafenib with TACE alone in patients with advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE+Sorafenib | TACE followed by Sorafenib |
| PROCEDURE | TACE | TACE alone |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-05-29
- Last updated
- 2016-03-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02150317. Inclusion in this directory is not an endorsement.